NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada (TASE:KMDA), a biopharmaceutical company which develops, manufactures and markets life-saving medicines, announces that following discussions with the EMEA (European Agency for the Evaluation of Medicinal Products), the company is planning a phase II clinical trial of the inhaled version of its Alpha-1 Antitrypsin [AAT] product to treat Cystic Fibrosis (CF). The phase I trial is currently in progress and shows good intermediate results. Kamada has also recently received EMEA approval for its plans for phases II/III clinical trials of AAT for treating Congenital Emphysema.
